Pharmacologic inhibition or genetic deletion of PPARγ in ILC2s abolished IL33-induced Th2 cytokine production and tumor growth in vivo, suggesting PPARγ inhibition as a target for ILC2-driven diseases beyond cancer (e.g., asthma, allergy). Here, PPARG is linked to neoplasm.